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A B S T R A C T
Peripheral Blood Mononuclear Cells (PBMCs) were collected from a patient with clozapine-resistant (also known as “su-
per-refractory”) Schizophrenia. iPSCs were established with a non-integrating Sendai virus-based reprogramming sys-
tem. A footprint-free hiPSC line was characterized to express the main endogenous pluripotency markers and to retain
a normal karyotype. Cells showed pluripotency competency by giving rise to progeny of differentiated cells belonging
to the three germ layers. This hiPSC line represents a valuable tool to obtain mature, pathology-relevant neuronal popu-
lations in vitro that are suitable to investigate the molecular background of the schizophrenic disorder and the resultant
patients' response to treatments.
© 2016 Published by Elsevier Ltd.
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Resource details
Blood samples were collected by a 48-year old male patient with a
diagnosis of disorganized and treatment-resistant Schizophrenia at the
Department of Mental Health of the San Paolo Hospital, Milan (Italy).
The diagnosis of Schizophrenia was confirmed by the assessment of
two independent psychiatrists with the Structured Clinical Interview
for DSM-IV Axis I Disorders (SCID-I). A thorough review of the pa-
tient's history confirmed treatment resistance according to specific cri-
teria (Caspi et al., 2004) but also resistance to clozapine, given lack of
response to the compound and to available pharmacological augmen-
tation strategies (Sommer et al., 2012).
To generate the SCZ#3-4 iPSC line the four Yamanaka reprogram-
ming factors OCT4, SOX2, KLF4, and C-MYC (Takahashi et al.,
2007) were delivered into PBMCs using the integration-free Sendai
virus (Fusaki et al., 2009; Yang et al., 2008-2012) gene-deliv
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Name of stem cell
line
SCZ#3-4 iPSC
Institution University of Trento
Person who cre-
ated resource
Silvio Scarone, Luciano Conti
Contact person
and email
Silvio.Scarone@unimi.it; luciano.conti@unitn.it
Date archived/
stock date
December 2015
Origin Peripheral Blood Mononuclear Cells (PBMCs)
Type of resource Induced pluripotent stem cells (iPSCs) derived from a schizo-
phrenic (confirmed with SCID-I) Clozapine Non-Responder
patient
Sub-type Induced pluripotent stem cells (iPSCs)
Key transcription
factors
hOCT4, hSOX2, hC-MYC, hKLF4 (CytoTune™-iPS 2.0
Sendai Reprogramming Kit - Thermo Fisher Scientific)
Authentication Identity and purity of the cell lines was confirmed by SeV spe-
cific polymerase chain reaction (PCR), pluripotent proteins de-
tection (Western Blot and immunocytochemistry), karyotyp-
ing, expression of specific markers of the three germ layers by
means of in in vitro differentiation
Link to related lit-
erature
/
Information in
public databases
/
Ethics Patient informed consent obtained; Ethics Review Board-com-
petent authority approval was obtained from the San Paolo
Hospital Ethical Board
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ery method (CytoTune-iPS 2.0 Sendai Reprogramming Kit; Thermo
Fischer Scientific). iPSC-like colonies appeared after 10–12 days and
were picked 6–7 days later (Fig. 1A). One of the clones gave rise
to the stable expanding SCZ#3-4 iPSC line with a clear iPSC-like
morphology (Fig. 1A) and uniform and specific OCT4, SOX2 and
TRA1-60 immunoreactivity (Fig. 1A). Expression of pluripotency
markers was also confirmed by PCR (Fig. 1B) and by Western Blot
(Fig. 1C) analyses. SCZ#3-4 iPSC line displayed a normal diploid 46,
XY karyotype, without appreciable abnormalities (Fig. 1B). The ab-
sence/presence of Sendai virus genome in cultures at passage 0 and
passage 10 was analyzed by PCR and the loss of the viral genome was
confirmed in passage 10 SCZ#3-4 iPSCs (Fig. 1B).
Pluripotent competence SCZ#3-4 iPSC line was assessed by Em-
bryoid Body assay. Cells were cultured for 7 days in EB suspension
and for additional 7 days in adhesion to promote the in vitro matura-
tion towards the three germ layer derivatives (Carpenter et al., 2003).
EBs cultures at 14 days displayed the presence of differentiated cells
immunoreactive for ectodermal (β3-Tubulin), mesodermal (α-SMA)
and endodermal (TROMA-1) markers (Fig. 2A). The differentiation
competency of SCZ#3-4 iPSCs was comparable to that observed for
a counterpart commercial hiPSC line, as shown by the similar ex-
pression levels of transcripts for FGF5 (ectoderm marker), Nestin
(neuro-ectoderm marker), T-Brachyury (mesoderm marker), SOX-17
(endoderm marker) assessed by qRT-PCR (Fig. 2B).
Materials and methods
PBMCs collection and freezing
Peripheral Blood Mononuclear Cells (PBMCs) from patients were
isolated in BD Vacutainer CPT Cell Preparation tubes with sodium
citrate, after 30 min centrifugation (1800 × g at room temperature).
PBMCs were collected in PBS for a total volume of 35 ml and cen-
trifuged at 300 × g for 15 min RT and resuspended in fetal bovine
serum (FBS) with 10% DMSO. 2 × 106 cells were aliquoted and
frozen.
Fig. 1. Characterization of SCZ#3-4 iPSC line. A: Representative picture of a SCZ#3-4 hiPSC colony (5 ×) and its karyogram displaying a normal diploid 46, XY karyotype with
no manifest cytogenetic abnormalities. Immunophenotypical characterization presenting the expression of the pluripotency markers OCT4, TRA-1-60, SOX2 (40 ×). B: RT-PCR
showing the expression of the pluripotency-associated genes in passages 0 and 10 in SCZ#3-4 iPSCs cultures and in another hiPSC clone (#3-14) derived from the same patient. Lack
of Sendai virus genome maintenance is presented in passage 10 cultures. A commercial hiPSC line was used as positive control for pluripotency-associated genes. C: Western Blot
analysis showing protein expression levels of pluripotency-associated markers (NANOG, SOX2, TRA1-60, OCT4) in SCZ#3-4 iPSCs and in other clones derived from the same
patient.
Fig. 2. In vitro differentiation SCZ#3-4 iPSC line. A: Embryoid Bodies formation assay after 4 days of suspension culture (5 ×). D14 cultures exhibit cells immuonoreactive for
ectodermal (β3Tubulin), mesodermal (α-SMA) and endodermal (TROMA-1) germ layer markers (20 ×). B: qRT-PCR showing an analogous expression levels of transcripts for the
3 germ-layers, FGF5 (ectoderm), Nestin and β3-Tubulin (neuro-ectoderm), T-Brachyury (mesoderm) and AFP (endoderm) between 14 days differentiated SCZ#3-4 and SCZ#3-14
iPSCs and differentiated reference commercial hiPSCs.
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PBMCs thawing and reprogramming with Sendai virus particles
PBMCs were thawed at 37 °C and centrifuged at 200 × g for
10 min in expansion medium (EM) made of StemPro-34 Serum Free
Medium (SFM, Thermo Fisher Scientific) Basal Medium, StemPro-34
Nutrient Supplement, 200 mM GlutaMAX, 1% Penicillin/Strepto-
mycin, 100 ng/ml Stem Cell Factor (SCF, Prepotech), 100 ng/ml
FLT-3 (Thermo Fisher Scientific), 20 ng/ml Interleukin-6 (IL-6)
(Thermo Fisher Scientific), 20 ng/ml Interleukin-3 (IL-3) (Thermo
Fisher Scientific). The medium was replaced daily for the following
3 days.
In order to deliver reprogramming genes in PBMCs, viral parti-
cles provided with the CytoTune-iPS 2.0 Sendai Reprogramming Kit
(Thermo Fisher Scientific) were used following the manufacturer's
protocol. 20 days post-transduction colonies with iPSCs morphology
appeared and were picked, transferred onto a new well and cultured on
Geltrex-coated plastic dish in E8 medium according to the manufac-
ture's protocol.
In vitro differentiation
Embryoid Bodies (EB) formation assay was performed by gen-
tly resuspending iPSCs clumps in 100-mm non-tissue culture-treated
dish in Essential 6 medium (E6 medium; Thermo Fisher Scientific).
Medium was changed daily. At day 7, EBs were collected and plated
on Geltrex-coated dishes in E6 medium to allow growth in adhesion
for further 7 days. Medium was changed every other day.
RNA isolation, polymerase chain reaction (PCR) and
quantitative-PCR (qPCR)
RNA was isolated with the TRIzol Reagent (Thermo Fisher Scien-
tific) following the manufacture's protocol and reverse transcribed us-
ing iScript cDNA Synthesis Kit (BioRad). Transcripts of interest were
amplified using EURO TAQ Thermostable DNA polymerase (EURO-
CLONE) and detection of genes of interest was confirmed with spe-
cific primes (Table 1). Quantitative Reverse Transcription-Polymerase
Chain Reaction (qRT-PCR) was performed using the SsoAdvanced
Universal SYBR Green Supermix Kit following the manufacturer's
instructions. Beta-actin was used as housekeeping gene to normalize
data. Amplification was performed on a CFX96 BioRad machine. Re-
sults were analyzed with BioRad CFX Manager dedicated software.
Immunofluorescence assay
Cells were fixed with PFA 4% for 15 min RT, permeabilized with
Triton 0.5% for 15 minutes RT and blocked with blocking solution
(10% FBS in PBS) for 1 h at RT. Cultures were then incubated with
specific primary antibodies overnight at 4 °C (Table 2) and stained
for 45 min at RT with secondary antibody and Hoechst 33258 1 μg/
ml (Thermo Fischer Scientific). Images were detected with the micro-
scope Leica DM IL Led Fluo with Leica DFC450 C camera (Leica
Microsystem).
Western Blot assay
Cultures were lysed in SDS Sample Buffer (62.5 mM Tris-HCl
ph 6.8; 2% SDS; 10% Glycerol; 50 mM DTT; Bromophenol Blue).
Samples were boiled at 95 °C for 5 min and loaded in the 8% poly-
acrylamide gel and proteins blotted on a PVDF membrane by means
of Trans Blot Turbo apparatus (BioRad). Primary antibodies (Table
2) were incubated overnight at 4 °C in agitation and secondary anti-
body for 45 min at RT. Signal was detected with the ECL Clarity sys-
tem (BioRad) in dark chamber UVITECH Cambridge (Uvitech) and
Uvitech software was used to acquire and analyze the data.
Karyotyping
Cell cultures were treated with colcemid (Gibco KaryoMAX Col-
cemid solution in PBS, Thermo Fischer Scientific) at a final concen-
tration of 10 ng/ml for 16 h (overnight) at 37 °C and metaphases har-
vest was carried out according to standard protocols. Briefly, PBS
washed cells were treated with hypotonic solution (0.075 M KCl for
15 min at RT) and fixed in acetic acid/methanol (1:3 v/v). Air-dried
metaphase spreads slides were analyzed by QFQ banding following
standard procedures. Microscope observation was performed using a
Nikon Eclipse 90i (Nikon Instruments, Japan) equipped with the ac-
quisition and analysis Genikon software (Nikon Instruments S.p.a.
Italy).
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Table 1
List of primers sequences, amplicons size and number of PCR cycles.
Gene Primer sequence Amplicon size Cycles (PCR)
BETA ACTIN F: GACAGGATGCAGAAGGAGATTACTG R: CTCAGGAGGAGCAATGATCTTGAT 72 bp 25
OCT4 F: GGAAGGAATTGGGAACACAAAGG R: AACTTCACCTTCCCTCCAACCA 71 bp 30
SOX2 F: GCTACAGCATGATGCAGGACCA R: TCTGCGAGCTGGTCATGGAGTT 135 bp 30
c-myc F: CCTGGTGCTCCATGAGGAGAC R: CAGACTCTGACCTTTTGCCAGG 128 bp 30
KLF4 F: CATCTCAAGGCACACCTGCGAA R: TCGGTCGCATTTTTGGCACTGG 156 bp 30
NANOG F: CCTGTGATTTGTGGGCCTG R: GACAGTCTCCGTGTGAGGCAT 78 bp 30
SEV F: GGATCACTAGGTGATATCGAGC R: ACCAGACAAGAGTTTAAGAGATATGTATC 181 bp 35
Nestin F: GGAGAAGGACCAAGAACTG R: ACCTCCTCTGTGGCATTC 153 bp qRT-PCR
T-Brachyury F: CCTTCAGCAAAGTCAAGCTCACC R: TGAACTGGGTCTCAGGGAAGCA 153 bp qRT-PCR
FGF5 F: GGAATACGAGGAGTTTTCAGCAAC R: CTCCCTGAACTTGCAGTCATCTG 99 bp qRT-PCR
AFP F: GCAGAGGAGATGTGCTGGATTG R: CGTGGTCAGTTTGCAGCATTCTG 113 bp qRT-PCR
β3-Tubulin F: TCAGCGTCTACTACAACGAGGC R: GCCTGAAGAGATGTCCAAAGGC 120 bp qRT-PCR
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Table 2
List of the antibodies used in for immunocytochemistry (IC) and Western Blot (WB)
assays, working dilution and species in which they are produced.
Antibody Company Dilution Species
TRA1-60 Santa Cruz
Biotech
1:1000 (WB) 1:200
(IC)
Mouse
IgM
NANOG Santa Cruz
Biotech
1:1000 Mouse
SOX2 Millipore 1:2000 (WB) 1:300
(IC)
Rabbit
OCT4 (WB) Santa Cruz
Biotech
1:1000 Mouse
LAMIN A/C Santa Cruz
Biotech
1:1000 Rabbit
OCT4 (IC) Santa Cruz
Biotech
1:100 Rabbit
α-SMA Sigma 1:100 Mouse
TROMA-1 Iowa DHB 1:100 Mouse
AFP Abnova 1:50 Rabbit
β3-Tubulin Promega 1:1000 Mouse
Anti-rabbit HRP BioRad 1:3000 Goat
Anti-mouse HRP BioRad 1:3000 Goat
Anti-mouse IgM FITC Santa Cruz
Biotech
1:200 Goat
Alexa Fluor IgG anti-rabbit
568
Life Technologies 1:300 Goat
Alexa Fluor IgG anti-rabbit
488
Life Technologies 1:300 Goat
Anti-mouse IgM FITC Santa Cruz
Biotech
1:200 Goat
Alexa Fluor IgG anti-
mouse 568
Life Technologies 1:400 Donkey
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